Sanofi releases Q3 2021 memorandum for modeling purposes
Sanofi has released its Q3 2021 Memorandum for modeling purposes on the company's investor website. The document aids analysts in modeling the company's financial results.
Paris, France – September 24, 2021 – Pharmaceutical company Sanofi announced today the availability of its memorandum for the third quarter of 2021, intended for financial modeling purposes. The document is accessible on the "Investors" section of Sanofi's corporate website.
As is customary each quarter, Sanofi prepares this memorandum to assist analysts and investors in building financial models for the company's quarterly performance. It provides details on non-comparable items, loss of exclusivity impacts, foreign currency effects, and share count.
The company's official third-quarter 2021 financial results are scheduled for publication on October 28, 2021. Sanofi previously reported stable revenues for the second quarter of 2021, despite volume declines in certain pharmaceutical areas, and has anticipated strengthening its vaccine portfolio.
Sanofi is a global biopharmaceutical company focused on human health. Its operations include disease prevention through vaccines and innovative treatments for various conditions, ranging from rare diseases to chronic long-term illnesses. Sanofi aims to translate scientific innovation into healthcare solutions worldwide, employing over 100,000 people across 100 countries.